Omic.ly Weekly 81

June 30, 2025

Hey There!

Thanks for spending part of your week with Omic.ly!


This Week's Headlines

1) No sequencer needed: Imaging based single-cell multiomics

2) Microbiomes are complicated and if you want to understand them you better start with good data

3) What did Watson and Crick actually discover?

4) Weekly Reading List


STAMP brings us non-destructive single-cell profiling without the sequencing

Single-cell transcriptomic profiling has emerged in recent years as a powerful tool for understanding the biology of complex cellular mixtures and tissues.

It's been used extensively to look at how cells respond to changing environments, tease apart the dynamics of disease states, and track cell fates during development.

And looking at single-cells is important because the activities of cell populations or rare individual cells can get washed out in bulk measurements of cellular material.

So, understanding the role that individual cells play in development, the function of a tissue, or even the development of cancer can be really important!

Unfortunately, one of the biggest challenges facing the field of single-cell transcriptomics is that it's very expensive and requires a ton of sequencing to get useful information out of each cell.

The methods for isolating cells can also be technically challenging, influence what genes are expressed or even bias the results against specific cell populations that are hard to isolate.

The go-to methods in single-cell fall into four broad categories:

Flow Assisted Cell Sorting - A cell sorter is used to separate single cells and spit them out individually into a microtiter plate

Droplet-based Microfluidics - single cells are encapsulated in an oil droplet with reagents that lyse the cell and barcode the contents for sequencing

Microwells - Cells are distributed across wells of a microplate with the hope that each well only ends up getting a single cell

Combinatorial Barcoding - Cells are combined across multiple plates each containing unique barcodes - new barcodes are ligated after each move which results in each cell ending up with a unique barcode!

But what ALL of these methods have in common is that they end up destroying the cells and turning them into sequencing libraries.

This means those cells can't be used for any other downstream analyses like proteomic profiling.

It also means you're probably going to spend a lot of money sequencing these things!

But as single-cell studies have increased in popularity, so have spatial studies!

These two things are related but different, in single-cell you're isolating and looking at...single-cells - in spatial, you're usually looking at where transcripts and proteins are located in tissue sections on slides.

Most of the latest generation of spatial techniques use imaging to locate transcripts and antibody bound proteins which makes them a bit cheaper because they don't require sequencing AND they have the added benefit that the tissue sections are not destroyed during the different analyses.

Now, some smart people have realized that you can use these spatial imaging systems to also look at single-cells!

They've developed something called Single-Cell Transcriptomics Analysis and Multimodal Profiling (STAMP) and basically what's done here is that single-cell suspensions are fixed and permeabilized using formaldehyde, bound to a microscope slide, and then processed like they're any old tissue sample going into the spatial imaging process!

It's one of those things that's so simple and cool it makes you wonder why it took people so long to figure out this was possible!

The results of this work can be seen in the figure above where a STAMP experiment was carried out with a 3-way mixture of MCF-7, LNCaP, and SK-BR-3 cancer cells on the CosMx platform.

A) shows the cell segmentation and transcript detection analysis, B) highlights that they get a lot of data from a lot of cells, and C,D,E) show they're able to easily discriminate the cells within the mixture!

They go on to show that they can detect a single MCF-7 cell in mixtures of millions of cells (1:100,000, 1:50,000) which highlights the impressive sensitivity of the technique for profiling things like circulating tumor cells in blood samples.

But the coolness doesn't stop there, because this technique is non-destructive so you can also do spatial proteomic profiling or analyze the samples across multiple different instruments.

The authors estimate that this technique will end up costing about $0.003 per cell which is kind of mindblowing when the average cost for a traditional sequencing based single-cell experiment is in the $0.10 range.

Now, there are drawbacks such as this technique doesn't produce full length transcripts so if you're into that you'll have to stick with the sequencing based techniques!

But STAMP looks like an interesting (and cheap) option for doing single-cell proteo-transcriptomics on a budget!

###

Pitino E, et al. 2025. STAMP: Single-cell transcriptomics analysis and multimodal profiling through imaging. Cell. DOI: 10.1016/j.cell.2025.05.027


So, you want to learn more about your microbiome?

Cool, here's what you need to know!

The human microbiome is the entire community of microorganisms that live on or in your body and is made up of bacteria, fungi and viruses.

Your body contains, or has on it, many different microbiomes.

This is because each crack, crevice, surface, and orifice creates a distinct environmental niche that promotes the growth of totally different microorganisms!

Meaning, your skin, your mouth, your armpits, and your gut have different microbiomes.

But it doesn't stop there, your gut microbiome itself can be segmented into different microbiomes because your upper and lower gastrointestinal tract create completely different environments.

So If you want to learn about your microbiome, you need to pick one, or choose a service that gives you multiple swabs to test them all!

Well, all except your upper GI, that one's a bit tough to do yourself, even if you have a reeallly long swab.

Once you've settled on which one you want to test you need to pick a service provider.

This is a pretty crowded space but I'm going to let you in on a little secret.

Most of these tests are actually just a resold product from a handful of vendors who provide 'white label' services, so you're mostly getting the same thing from everyone.

And what you're generally getting is a read-out of your microbial community based on 16s ribosomal sequencing.

Now, only bacteria contain a 16s gene so the vast majority of services aren't really reporting out a true microbiome because they're missing all the fungi and viruses!

But to make matters worse, most of these services only sequence a small fraction of the 16s gene, the V4 hypervariable region.

You might be thinking, 'hypervariable sounds good!'

Except the 16s gene is 1600 bases long and has 9 hypervariable regions...

Sequencing just one of them is not going to give you the most accurate representation of your community.

And if you really want to do this right, you'd do 16s-ITS-23s.

Except you can't sequence that unless you use **drum roll** long-reads because it's ~4,500bp!

Microbiome sequencing is yet another example of a situation where 'friends don't let friends short-read,' especially if you actually care about identifying species or subspecies level community composition.

There are products that claim they can get species level descrimination from just V4.

But don't be fooled!

While they can detect about 50% of species with just V4, you really need all 9 hypervariable regions to get a species level identification for all of the taxa in a sample.

Otherwise, the best you can do is a genus level identification.

So, what do you actually get out of doing a direct to consumer microbiome analysis?

That's a good question.

There's general agreement that the microbiome is important, but what we can actually learn by sequencing it, other than saying there's some bacteria there, is still a work in progress.


History is written by victors, and that statement couldn't be more true than it is in the case of Watson and Crick's 'discovery' of the DNA double helix.

Their structure was published in the April 1953 issue of Nature along with two other papers on the same topic from Wilkins and Rosalind Franklin.

Although they don't cite Franklin in their 1953 paper, they definitely used her data.

It was Franklin's paper that included Raymond Gosling's pristine diffraction of B-DNA, known as Photo 51, that showed the structure of DNA is helical, it's double stranded, and the bases faced inward with the phosphate backbone on the outside.

While this is a good chunk of what you need to know to put the structure of DNA together, there were a couple of additional missing pieces that the boys from the Cavendish Lab had to source.

What gets lost in all of the popular coverage of this discovery is that Watson and Crick didn't perform any experiments, they aggregated the best science at the time to create their model.

Franklin wasn't the only person they borrowed from.

Phoebus Levene's life was spent studying DNA, he's why we call the bases nucleotides and he showed that DNA has a 5'-3' deoxyribose sugar phosphate backbone but also that the bases are composed of adenine, thymine, guanine, and cytosine.

Erwin Chargaff shared with them what he knew about the ratios of the bases, or Chargaff's rule, which is that A and T, and G and C are found paired in a 1:1 ratio.

He had a famously checkered opinion of the duo and even went as far as to say, "I told them all I knew. If they had heard before about the pairing rules, they concealed it. But as they did not seem to know much about anything, I was not unduly surprised."

Next on the list was hydrogen bonding between the bases. This little known fact was cribbed from the thesis work of a graduate student at the time, June Broomhead (Lindsey), who also proposed all of the possible structures for A, T, G and C.

But knowledge of that final piece of the puzzle came from Jerry Donohue who shared an office at Cambridge with Crick.

He noticed that Crick was trying to pair up the bases using their 'enol' forms and so Donohue suggested, based on Broomhead's work, that Crick should try to smash the 'keto' forms together instead because they were much more common.

The figure above is Crick's smashing result: Watson-Crick(-Broomhead-Donohue?) base-pairing. It was published in 1954 in a much longer and more detailed follow-up paper on the structure of DNA.

While historic, this story is nuanced, and I'll leave you with Crick's measured interpretation of the situation.

"What, then, do Jim Watson and I deserve credit for? The major credit I think [we] deserve … is for selecting the right problem and sticking to it."

I tend to agree.

###

Crick FHC, Watson JD. 1954. The Complementary Structure of Deoxyribonucleic Acid. Proc. R. Soc. A. DOI:10.1098/rspa.1954.0101


Weekly Reading List

Palm Beach Gardens Man wants to revive disgraced Theranos brand
A local inventor is trying to make a name for himself in a rather unusual way.
Eric Green was the first institute director forced out of NIH. He still hasn’t been told why
Eric Green said the process leading to his ouster as a NIH institute director by the Trump administration remains “shrouded in mystery”
Mapping the Transcriptional Landscape of Drug Responses in Primary Human Cells Using High-Throughput DRUG-seq
To advance our understanding of drug action in physiologically-relevant systems, we developed a high-throughput transcriptomic atlas of compound responses in primary human cell types. Leveraging the scalable and cost-effective Digital RNA with the pertUrbation of Genes (DRUG-seq) assay, we profiled gene expression responses to 89 pharmacologically-active compounds across six concentrations in four distinct primary cell types: aortic smooth muscle cells (AoSMCs), skeletal muscle myoblasts (SkMMs), dermal fibroblasts, and melanocytes.
Genetic disease risks of under-represented founder populations in New York City
Author summary It is well recognized that genomic studies have been biased towards individuals of European ancestry, and that obtaining medical insights for populations under-represented in medical genomics is crucial to achieve health equity. Here, we use genomic information to identify networks of individuals in New York City who are distinctively related to each other, allowing us to define populations with common genetic ancestry based on genetic similarities rather than by self-reported race or ethnicity. In our study of >25,000 New Yorkers, we identified seven highly-interrelated founder populations, with 201 likely disease-causing variants with increased frequencies in specific founder populations. Many of these population-specific variants are new discoveries, despite their high frequency in founder populations. Studying recent genetic ancestry can help reveal population-specific disease insights that can help with early diagnosis, carrier screening, and opportunities for targeted therapies that all help to reduce health disparities in genomic medicine.
Predicting resistance to chemotherapy using chromosomal instability signatures - Nature Genetics
Here the authors show that chromosomal instability signatures can predict resistance to anthracycline-, taxane- and platinum-based chemotherapeutics in breast, ovarian and prostate cancer and sarcoma. Validation is performed through emulation of phase 2 and 3 clinical trials using real-world data.
Paleolake geochronology supports Last Glacial Maximum (LGM) age for human tracks at White Sands, New Mexico
Discovery of human footprints in alluvium dated to the Last Glacial Maximum (LGM) at White Sands, New Mexico, was a notable step in understanding the initial peopling of the Americas, but that work was met with criticism focused on the reliability of the materials used in the radiocarbon dating (seeds of Ruppia and pollen). This paper reports on an independent study of the chronology of a previously unrecognized stratigraphic record of paleolake Otero that is directly traceable into the track-bearing alluvium.
Millions of children at risk as vaccination uptake stalls
A global study finds large numbers of children are unvaccinated against diseases like measles, tuberculosis and polio, which makes outbreaks more likely.
llumina to Acquire SomaLogic Assets from Standard BioTools for up to $425M
Illumina said Monday that it will acquire proteomics technology originally developed by SomaLogic, among other assets, from Standard BioTools for $350 million in cash. The deal also includes up to $75 million in near-term milestone cash payments and performance-based royalties.
RFK Jr. defends proposed HHS budget as Democrats slam cuts, gutting of CDC vaccine panel
Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. | HHS Secretary Robert F. Kennedy Jr. defended his reorganization of the agency and the proposed fiscal 2026 budget that cuts funding by 25% during a hearing Tuesday of the House Energy and Commerce Health subcommittee.
Cassidy calls to delay meeting of CDC’s vaccine panel in challenge to RFK Jr.
A key GOP senator is calling for the CDC’s vaccine meeting to be postponed after RFK Jr. shook up the panel.
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity
Biased agonism of G protein-coupled receptors (GPCRs) offers potential for safer medications. Current efforts have explored the balance between G proteins and β-arrestin; however, other transducers like GPCR kinases (GRKs) remain understudied. GRK2 is essential for β2 adrenergic receptor (β2AR)-mediated glucose uptake, but β2AR agonists are considered poor clinical candidates for glycemic management due to Gs/cyclic AMP (cAMP)-induced cardiac side effects and β-arrestin-dependent desensitization. Using ligand-based virtual screening and chemical evolution, we developed pathway-selective agonists of β2AR that prefer GRK coupling.
Infectome analysis of bat kidneys from Yunnan province, China, reveals novel henipaviruses related to Hendra and Nipah viruses and prevalent bacterial and eukaryotic microbes
Author summary Although extensive investigations have been conducted on the bat virome, most studies have focused on fecal samples, leaving other tissues, such as the kidney, largely unexplored. However, the kidney can harbor important zoonotic pathogens, including the highly pathogenic Hendra and Nipah viruses, and genomic evidence of henipaviruses in bats from China has remained undocumented. In this study, we report the first detection of two novel henipavirus genomes from bat kidneys in China, one of which is the closest known relative of pathogenic henipaviruses identified to date. Beyond virome analysis, our study also examined highly prevalent bacteria and eukaryotic microbes, identifying those potentially relevant to bat infections. Overall, these findings provide valuable insights into the infectome of the bat kidney, highlighting the need for broader microbial surveillance beyond the gastrointestinal tract.
Clinical report outlines how, why to pursue genetic diagnosis for GDD/ID Free
Global developmental delay and intellectual disability (GDD/ID) in children are common concerns primary care pediatricians face. GDD/ID have diverse etiologies, but genetic disorders account for a substantial percentage. Establishing a genetic diagnosis provides multiple benefits for the patient and family, including improvements in patient care and determination of recurrence risk.
AlphaGenome: AI for better understanding the genome
Introducing a new, unifying DNA sequence model that advances regulatory variant-effect prediction and promises to shed new light on genome function — now available via API.
Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer
Homologous recombination deficiency (HRD) is a genomic feature present in some malignant neoplasms and is attributed to the failure of the homologous recombination repair pathway. Tumors with an HRD-positive status may have a distinct prognosis and/or response to therapies, including poly (ADP-ribose) polymerase inhibitors. The Association for Molecular Pathology assembled an expert panel to examine current practice and perform a scoping review of the medical literature pertaining to the molecular detection of HRD in the clinical setting.
MPSE identifies newborns for whole genome sequencing within 48 h of NICU admission - npj Genomic Medicine
npj Genomic Medicine - MPSE identifies newborns for whole genome sequencing within 48 h of NICU admission
Correction of pathogenic mitochondrial DNA in patient-derived disease models using mitochondrial base editors
Recent developments in base editing technologies enable the correction of mutations in the mitochondrial genome, but its therapeutic potential remains unclear. This proof-of-principle study shows that mitochondrial base editing can functionally create and correct mitochondrial pathogenic mutations in patient-derived cells.
CDC panel, newly remade by RFK Jr., questions vaccine evidence
New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.
Judge overturns NSF’s 15% cap on reimbursing indirect costs of research
Agency’s action deemed in violation of federal law
Nerve-to-cancer transfer of mitochondria during cancer metastasis - Nature
A study reports the development of a method to trace intercellular transfer of mitochondria, and demonstrates that cancer cells that receive mitochondria from neurons have enhanced metastatic capabilities.
uv, part 4: uv with Jupyter
Using uv with Jupyter: demo using polars and seaborn for analysis and visualization.
Artificial Intelligence in Proteomics Workflows Takes off
Artificial intelligence and deep learning are carving out substantial roles in proteomic workflows, improving peptide and protein identifications, advancing applications like de novo sequencing, and allowing scientists to more accurately and comprehensively model biological systems.
French scientists discover new blood type in Guadeloupe woman
Thanks to DNA sequencing, the discovery of new blood groups has accelerated in recent years.
ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing
The American College of Medical Genetics and Genomics (ACMG) previously published guidance for reporting secondary findings (SFs) in the context of clinical exome and genome sequencing.1-7 The ACMG Secondary Findings Working Group (SFWG) and Board of Directors (BODs) have agreed that the list of recommended genes should be updated annually and with an ongoing goal of maintaining this as a minimum list. Reporting of SFs should be considered neither a replacement for indication-based diagnostic clinical genetic testing nor a form of population screening.
Fine-mapping genomic loci refines bipolar disorder risk genes - Nature Neuroscience
This study used fine-mapping to analyze genetic regions associated with bipolar disorder, identifying specific risk genes and providing new insights into the biology of the condition that may guide future research and treatment approaches.
The New ‘Razor Blade Throat’ Nimbus COVID Variant: Symptoms, Incubation Period and When to Test | KQED
A new COVID variant called “Nimbus” is spreading. Here’s what you need to know about the incubation period, symptoms (including “razor blade throat”) and when to take a test.
Supreme Court Preserves ACA Preventive Requirements for Private Plans; Rejects Challenge to USPSTF
The Affordable Care Act of 2010 requires private insurance to cover preventive benefits endorsed by the USPTF. The legitimacy of the USPS…
Common and rare genetic variants show network convergence for a majority of human traits
While both common and rare variants contribute to the genetic etiology of complex traits, whether their impacts manifest through the same effector genes and molecular mechanisms is not well understood. Here, we systematically analyze common and rare variants associated with each of 373 phenotypic traits within a large biological knowledge network of gene and protein interactions. While common and rare variants implicate few shared genes, they converge on shared molecular networks for more than 75% of traits. We demonstrate that the strength of this convergence is influenced by core factors such as trait heritability, gene mutational constraints, and tissue specificity. Using neuropsychiatric traits as examples, we show that common and rare variants impact shared functions across multiple levels of biological organization. These findings underscore the importance of integrating variants across the frequency spectrum and establish a foundation for network-based investigations of the genetics of diverse human diseases and phenotypes. ### Competing Interest Statement T.I. is a co-founder, member of the advisory board, and has an equity interest in Data4Cure and Serinus Biosciences. T.I. is a consultant for and has an equity interest in Ideaya Biosciences and Eikon Therapeutics. The terms of these arrangements have been reviewed and approved by the University of California, San Diego, in accordance with its conflict-of-interest policies. ### Funding Statement This work was supported by the following grants from the National Institutes of Health: NIMH U01 MH115747 to T.I., and NIDA P50 DA037844 to T.I. This work was also supported by the following grants from the California Institute for Regenerative Medicine: ReMIND DISC4-16322 and ReMIND DISC4-16377. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All human data utilized in this study were openly available before the initiation of the study. Summary results from previously published genome wide association studies (GWAS) were sourced from the GWAS Catalog (https://www.ebi.ac.uk/gwas/api/search/downloads/alternative). Accession numbers for the studies used can be found in Supplemental Table 1. Summary results from previously published gene-level rare variant studies were sourced from the Rare Variant Association Repository (RAVAR, http://www.ravar.bio/api/download/static/gene_fulltable.txt). Publication identifiers (PMIDs) for the studies used can be found in Supplemental Table 1. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript <https://www.ebi.ac.uk/gwas/api/search/downloads/alternative> <http://www.ravar.bio/api/download/static/gene_fulltable.txt>

Were you forwarded this newsletter?

LOVE IT.

If you liked what you read, consider signing up for your own subscription here:

Subscribe to Omic.ly